In this phase II study, 41 patients with locally advanced urothelial bladder cancer (T2-4, NO, MO) were treated with primary chemotherapy (cisplatin, epirubicin, methotrexate: PEM-3). All the patients were assessable for response and toxicity. Clinical monitoring was performed with computerized tomography and cystoscopy. Nineteen clinical complete remissions (46%) and 10 partial remissions (24.5%) were obtained (CR + PR, 70.5%; 95% confidence interval, 57%-85%). Ten patients were considered to have clinically stable disease (24.5%), and 2 patients progressed (5%). Surgery after chemotherapy was performed in 22 cases: in 6 patients (27%) a pathologic complete response was achieved. The pathologic stage was lower than the initial clinical stage in 13 patients (59%). After a median follow-up of 3 years (range, 1-4), the median time to progression was 104 weeks. At this writing, 20 patients, 12 of which were submitted to surgery and 8 were not operated, are disease-free. The 3-year survival rate is 52%. No one had to interrupt the treatment because of toxicity. In conclusion, the PEM-3 regimen is a very active and well-tolerated regimen in locally advanced bladder cancer.
BonadonnaG., Robustelli della CunaG.: Manuale di oncologia medica, Masson Editore, Paris, 1991.
2.
CrucianiG., DazziC., MontanariF., VoceS., SalernoV., GianniniM., EmilianiE., MarangoloM.: Conservative treatment for T2-T4 bladder cancer with primary chemotherapy and radiotherapy: a pilot study. Tumori, 79: 53–57, 1993.
3.
DreicerR., KollmorgenT., SmithR., WilliamsS.: Neoadjuvant cisplatin, methotrexate and vinblastine for muscle-invasive bladder cancer: long-term follow-up. J. Urol., 150: 849–852, 1993.
4.
FossaS.D., SplinterT., RoozendaalK.J., VeenhofK.H.N., Pavone MacalusoM., CalciatiA., De PauwM., SylvesterR.: A phase II study of 4-epi-adriamycin in advanced urothelial transitional cell cancer. Eur. J. Cancer Clin. Oncol., 25: 389–390, 1989.
5.
HarkerW.G., MeyersF.J., FreihaF.S., PalmerJ.M., ShortliffeL.D., HanniganJ.F., McWherterK.M., TortiF.M.: Cisplatin, methotrexate and vinblastine (CMV): an effective chemotherapy regimen on metastatic transitional cell carcinoma of the urinary tract: a NCOG study. J. Clin. Oncol., 3: 1463–1470, 1985.
6.
HatcherP., HahnR., RichardsonR., ZinckeH.: Neoadjuvant chemotherapy for invasive bladder carcinoma: disease outcome and bladder preservation and relationship to local tumor response. Eur. Urol., 25: 209–215, 1994.
7.
HerrH., WhitmoreW., MorseM., SoganiP., RussoP., FairW.: Neoadjuvant chemotherapy in invasive bladder cancer: the evolving role of surgery. J. Urol., 144: 1083–1088, 1990.
8.
HerrH., ScherH.: Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J. Clin. Oncol., 12: 975–980, 1994.
9.
LelliG., TononiA., CasadioM., SeveriniG., DeSantisF., PannutiF.: Cisplatin, epirubicin and methotrexate (PEM) in the treatment of urothelial cancer: a phase II trial. Proceed. 5th European Conference on Clinical Oncology, London, 3-7 Sept. 1989, abst. P-0565.
10.
LelliG., MelottiB., PannutiF., RossiA.P., MaverP., ManniniD., CorradoG., SeveriniG., BercovichE., BeghelliR., ConcettiS., ManferrariF., NanniP., DeSantisP., MartinelluA., and TannebergerS.: Chemotherapy with cisplatin, epirubicin, methotrexate in the treatment of locally advanced or metastatic transitional cell cancer of the bladder. J. Chemother., 4: 239–243, 1992.
11.
LelliG., MelottiB., MartoniA., StrocchiE., PannutiF.: Neoadjuvant cisplatin (P), epirubicin (E) and methotrexate (M) in invasive bladder cancer: a dose-intensity and dose-response study. Am. Soc. Clin. Oncol., 11: A650, 1992.
12.
MillerA.B., HoogstratenB., StaquetM., WinklerA.: Reporting results of cancer treatment. Cancer, 47: 207–214, 1981.
13.
PellegriniA.: Neoadjuvant treatment for locally advanced bladder cancer: a randomized prospective clinical trial (abstract). Proceeding 4th Int. Congress on anticancer chemotherapy, Paris, 1993, p. 105.
14.
ProutG., ShipleyW., KaufmanD., HencyN., GriffinP., AlthansenA., BassilB., NocksB., ParkhurstE., YoungH.: Preliminary results in invasive bladder cancer with transurethral resection, neoadjuvant chemotherapy and combined pelvic irradiation plus cisplatin chemotherapy. J. Urol., 144: 1128–1136, 1990.
15.
RaghavanD.: Pre-emptive (neoadjuvant) intravenous chemotherapy for invasive bladder cancer (review). Br. J. Urol., 61: 1–8, 1988.
16.
ScherH.: Chemotherapy for invasive bladder cancer: neoadjuvant versus adjuvant. Semin. Oncol., 17: 555–565, 1990.
17.
SeveriniG., BacchettiG., MaverP., ManniniP., LelliG., CasadioM., GuaraldiM., TononiA., PannutiF.: Risultati preliminari di un trattamento con cisplatino, epirubicina e metotrexate nel carcinoma vescicale in stadio avanzato. Acta Urol. Ital., 3: 142, 1988.
18.
ShipleyW.U.: Bladder conservation: current status and patterns of treatment failure. 36th Annual Clinical Conference and 25th Annual Special Pathology Program: patterns and mechanisms of failure after cancer treatment. Houston, p. 10–11, 1992.
19.
SternbergC.N., ScherH.I.: Advances in the treatment of urothelial tract tumors. Urol. Clin. North Am., 14: 373–387, 1987.
20.
SternbergC.N., YagodaA., ScherH.I., WatsonR.C., TauseefA., WeiselbergL.R., GellerN., HollanderP.S., HerrH.W., SoganiP.C., MorseM.J., WhitmoreW.F.: Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium. J. Urol., 133: 403–407, 1985.
21.
SternbergC., ArenaM., CalabresiF., De CarliP., PlataniaA., ZeuliM., GiannarelliD., CancriniA., PansadoroV.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for infiltrating transitional cell carcinoma of the bladder. Cancer, 72: 197–82, 1993.
22.
StoterG., SplinterT.A.W., ChildJ.A., FossaS.D., DenisL., Van OosteromA.T., De PauwM., SylvesterR.: Combination chemotherapy with cisplatin and methotrexate in advanced transitional cell cancer of the bladder. J. Urol., 137: 663–667, 1987.
23.
StoterG.: The role of chemotherapy in metastatic and muscle-invasive non-metastatic bladder cancer. Proceeding 5th European Conference on Clinical Oncology, London, 3-7 Sept. 1989, abst. S-32.
24.
TonkinK., TannockI.: Evaluation of response and morbidity following treatment of bladder cancer. In: The management of bladder cancer, RaghavanD. (Ed.), pp. 228–244, E. Arnold, London, 1988.
25.
VogelzangN., MoormeierJ., AwanA., WeichselbaumR., FarahR., StrausF., ShoenbergH., ChodakG.: Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer: the University of Chicago experience. J. Urol., 149: 753–757, 1993.
